利巴韦林气雾剂辅助治疗毛细支气管炎的疗效观察

发布时间：2019-04-17 20:17

【摘要】：目的毛细支气管炎,是婴幼儿时期常见的、以毛细支气管病变为主的一种下呼吸道感染性疾病。好发人群年龄为2岁以下的婴幼儿,特别是2~6个月以内的小婴儿最为高发。利巴韦林作为一种广谱抗病毒药物也一直被广泛应用,除静脉给药外,雾化吸入近年来在逐渐应用,但疗效也存在争议。为了探讨利巴韦林气雾剂辅助治疗毛细支气管炎的疗效,本文选取符合标准的106例毛支患儿,观察利巴韦林气雾剂辅助治疗毛支的疗效及有无明显不良反应。方法选取安徽省阜阳市第二人民医院儿科2011.1—2013.12月间收治的毛细支气管炎患儿106例,按照随机是否给予利巴韦林气雾剂分为治疗组(56例)与对照组(50例),两组患儿在年龄、性别、病程等方面均无显著性差异(p0.05),具有可比性。两组患儿均给予控制喘憋、氧疗、抗感染、联合应用硫酸沙丁胺醇、布地奈德和异丙托溴胺液进行雾化吸入等综合治疗。治疗组在此基础上同时给予利巴韦林气雾剂喷口腔,疗程3~5d。比较两组患儿咳嗽、憋喘、哮鸣音、湿Up音消失时间及有效率。计量资料用x-±s表示,采用t检验;计数资料用百分率表示;率的比较采用χ2检验,P0.05为差异有统计学意义。结果治疗组总有效率为92.9%,对照组为74%,组间比较有统计学意义(P0.05);治疗组患儿在憋喘(3.16±1.54vs4.84±1.96)、咳嗽(4.93±1.09vs7.52±1.20)、哮鸣音(4.58±1.49vs6.59±1.21)、湿Up音(5.41±1.25vs6.92±1.98)等方面的消失时间均短于对照组时间,两组间比较具有统计学意义(P0.05)。用药过程未发现有贫血等不良反应。结论治疗毛细支气管炎时加用利巴韦林气雾剂辅助治疗具有肯定的疗效,可以缩短症状体征消失的时间,提高治疗疗效,是治疗本病的有效方法,给药简单易行,易于接受,值得推广。
[Abstract]:Objective bronchiolitis is a common infective disease of lower respiratory tract in infants. High-risk infants under 2 years of age, especially those less than 2 months of age, had the highest incidence. Ribavirin, as a broad-spectrum antiviral drug, has been widely used. Besides intravenous administration, nebulization inhalation has been used gradually in recent years, but the curative effect is also controversial. In order to evaluate the efficacy of ribavirin aerosol in the treatment of bronchiolitis, 106 children with bronchiolitis were selected to observe the efficacy and adverse reactions of ribavirin aerosol in the treatment of bronchiolitis. Methods 106 children with bronchiolitis were randomly divided into treatment group (56 cases) and control group (50 cases) according to whether ribavirin aerosol was given or not in the pediatric department of the second people's Hospital of Fuyang City Anhui Province from January 2011 to March 2013.Results 106 cases of bronchiolitis were treated with ribavirin aerosol or not. There was no significant difference in age, sex and course of disease between the two groups (p0.05). All the children in both groups were treated with asthma control, oxygen therapy, anti-infection, combined with salbutamol sulfate, budesonide and isopropytobromine solution for atomization inhalation. On this basis, ribavirin aerosol was given to the treatment group at the same time, and the course of treatment was 3 d 5 d. The time and effective rate of cough, wheezing, wheezing and wet Up were compared between the two groups. The measurement data were expressed by x-table s and t-test, and the counting data were expressed by percentage. 蠂 2 test was used to compare the rate, P0.05 was statistically significant. Results the total effective rate was 92.9% in the treatment group and 74% in the control group (P0.05). In the treatment group, asthma (3.16 卤1.54vs4.84 卤1.96), cough (4.93 卤1.09vs7.52 卤1.20) and wheezing (4.58 卤1.49vs6.59 卤1.21) were observed. The disappearance time of wet Up sound (5.41 卤1.25vs6.92 卤1.98) was shorter than that of control group (P0.05). No adverse reactions, such as anemia, were found in the course of drug use. Conclusion addition of ribavirin aerosol in the treatment of bronchiolitis has definite curative effect, can shorten the time of disappearance of symptoms and signs and improve the therapeutic effect. It is an effective method to treat bronchiolitis. The administration of ribavirin aerosol is simple, easy to accept, and can be used in the treatment of bronchiolitis. It is worth popularizing.
【学位授予单位】：安徽医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R725.6

【相似文献】